1. Prognostic influence of loss of blood group A antigen expression in pathologic stage I non-small-cell lung cancer.
- Author
-
León-Atance P, Moreno-Mata N, González-Aragoneses F, Cañizares-Carretero MÁ, Poblet-Martínez E, Genovés-Crespo M, García-Jiménez MD, Honguero-Martínez AF, Rombolá CA, Simón-Adiego CM, Peñalver-Pacual R, and Alvarez-Fernández E
- Subjects
- Adenocarcinoma chemistry, Adenocarcinoma enzymology, Adenocarcinoma mortality, Adenocarcinoma pathology, Adenocarcinoma surgery, Aged, Aged, 80 and over, Carcinoma, Non-Small-Cell Lung chemistry, Carcinoma, Non-Small-Cell Lung mortality, Carcinoma, Non-Small-Cell Lung pathology, Carcinoma, Non-Small-Cell Lung surgery, Female, Humans, Immunoenzyme Techniques, Lung Neoplasms chemistry, Lung Neoplasms mortality, Lung Neoplasms pathology, Lung Neoplasms surgery, Male, Middle Aged, N-Acetylgalactosaminyltransferases genetics, N-Acetylgalactosaminyltransferases metabolism, Neoplasm Proteins genetics, Neoplasm Proteins metabolism, Neoplasm Staging, Pneumonectomy, Prognosis, Retrospective Studies, ABO Blood-Group System metabolism, Antigens, Neoplasm metabolism, Carcinoma, Non-Small-Cell Lung enzymology, Chromosome Deletion, Chromosomes, Human, Pair 9 genetics, DNA Methylation, Gene Deletion, Lung Neoplasms enzymology, N-Acetylgalactosaminyltransferases deficiency, Neoplasm Proteins deficiency
- Abstract
Introduction: In the scientific literature, contradictory results has been published on the prognostic value of the loss of expression of blood group antigen A (BAA) in lung cancer. The objective of our study was to analyze this fact in our surgical series., Patients and Methods: In a multicenter study, 402 non-small-cell lung cancer (NSCLC) patients were included. All were classified as stage-I according to the last 2009-TNM classification. We analyzed the prognostic influence of the loss of expression of BAA in the 209 patients expressing blood group A or AB., Results: The 5-year cumulative survival was 73% for patients expressing BAA vs 53% for patients with loss of expression (P=.03). When patients were grouped into stages IA and IB, statistical significance was only observed in stage I-A (P=.038). When we analyzed the survival according to histologic type, those patients with adenocarcinoma and loss of expression of BAA had a lower survival rate that was statistically very significant (P=.003). The multivariate analysis showed that age, gender and expression of BAA were independent prognostic factors., Conclusions: The loss of expression of blood group antigen A has a negative prognostic impact in stage I NSCLC, especially in patients with adenocarcinoma., (Copyright © 2011 SEPAR. Published by Elsevier Espana. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF